AASLD News
UDCA Treatment Lowers Biliary Tract Cancer, Need for Liver Transplantation in PSC Patients
Media Contact: Caroline Laurin Phone: (703) 299-9766 Email: media@aasld.org Alexandria, VA – Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that ursodeoxycholic acid (UDCA) treatment has significant, positive results for patients with primary sclerosing cholangitis (PSC), including
Unique Coagulation Driven By IL-6 Trans-Signaling Associated With Liver Injury In COVID-19
Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that COVID-19 coagulation impairment, driven in part by endothelial Factor VIII, is associated with liver injury in infected patients.
New Cases Of Hepatocellular Carcinoma Disproportionately Affecting Americans In Rural Areas New Study Shows
Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that the rate of new hepatocellular carcinoma (HCC) cases has slowed since 2009, but only in urban areas.
Alarming New Study Highlights Need For Improved Access To HBV Vaccination, Testing And Treatment
Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that in 2019, more than 500,000 persons died of hepatitis B virus infection, highlighting the urgent need for universal HBV vaccination of children beginning at birth, and scaling up testing and access to care and treatment before people with
More Women Diagnosed With HCV During Pregnancy, but Many Infants Still Not Tested Despite Recommendations From Leading Health Organizations
Media Contact: Caroline Laurin Phone: (703) 299-9766 Email: media@aasld.org Alexandria, VA – Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases (AASLD)– found that among pregnant women with hepatitis C virus (HCV), more than 25 percent were initially diagnosed during pregnancy screenings, which
AASLD's Newest Open-Access Journal To Receive First Impact Factor
Today the American Association for the Study of Liver Diseases (AASLD) announced that Hepatology Communications – AASLD’s free, open-access journal – has been accepted into Clarivate’s Science Citation Index Expanded (SCIE) and Journal Citation Reports – one of the leading citation indexes for journals of science and technology. The journal will now be eligible for an Impact Factor (IF) evaluation
AASLD President's Statement On 2020 Nobel Prize In Medicine
Join me and the AASLD in congratulating Drs. Harvey J. Alter, Michael Houghton, and Charles M. Rice, the 2020 recipients of the Nobel Prize in Physiology for Medicine. Their groundbreaking research identified the Hepatitis C virus (HCV) – a bloodborne pathogen that causes acute and chronic hepatitis, cirrhosis, and liver cancer – and laid the foundation for the future development of a cure.
AASLD Foundation Announces Funding of Over $2.2 Million in Research and Career Development Awards, Abstract Awards, and Emerging Liver Scholars Program
Alexandria, VA – The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest private supporter of liver disease research and training in the United States, today announced its combined investment of over $2.2 million in Research and Career Development Awards, Abstract Awards, and its Emerging Liver Scholars (ELS) Program. The 2020 award recipients — selected from a
Joint Gi Society Message: Racism, Social Injustice and Our Pledge To Lead Change
Dear Colleagues: The United States is experiencing the tragic consequences of racism. As health care providers, we have dedicated our lives to caring for our fellow human beings. Therefore, we are compelled to speak out against any treatment that results in unacceptable disparities that marginalize the vulnerable among us. As leaders of the four GI societies, AASLD, ACG, AGA, and ASGE, we stand
AASLD Releases Clinical Insight Guide For Treating Patients With Liver Disease And COVID-19
The American Association for the Study of Liver Disease (AASLD) has released a clinical insight document for clinicians and frontline healthcare providers who are treating patients with liver disease during the COVID-19 pandemic.
Joint Gi Society Message: COVID-19 Clinical Insights For Our Community Of Gastroenterologists And Gastroenterology Care Providers
The situation involving the COVID-19 pandemic continues to evolve. There is recent evidence suggesting the potential for coronavirus transmission through droplets and perhaps fecal shedding posing potential risks during endoscopy and colonoscopy to other patients, endoscopy personnel, and ourselves.
Hepatology Communications Editorial Fellowship
Hepatology Communications, AASLD’s online Open Access journal, is seeking candidates who are interested in a year-long Editorial Fellowship. Download the Editorial Fellowship description. Each candidate should submit the following documents to Olivia Potvin at opotvin@bidmc.harvard.edu by December 31, 2020.
Matthew R. D’Uva To Join AASLD As CEO
The American Association for the Study of Liver Diseases (AASLD) has appointed Matthew R. D’Uva, FASAE, CAE, as its new chief executive officer, effective January 21, 2020.
African Americans Face Significant Delays in Liver Transplantation Despite High Priority Scores
Media Contact: Caroline Laurin Phone: (703) 299-9766 Onsite phone: (415)-978-3601 Email: media@aasld.org San Francisco – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that African-American patients on waitlists for liver transplantation, despite severe disease and high scores for prioritization